Nova’s HydRIS platform can offer room temperature distribution & storage of live virus vector vaccines including: MVA, adeno virus vectors which can be part of the solution in controlling the current Ebola outbreak
HydRIS (Hypodermic Rehydration Injection System)
Highly labile products, such as live viral vector vaccines are not particularly suited to a conventional drying process.
HydRIS platform has been proven to be highly successful in stabilising a range of live biologics:
-
Live viral vector vaccines (adeno, MVA)
-
Flavivirus
-
listeria monocytogene based vector
-
Range of live veterinary vaccines
-
Range of extremely labile, protein based therapeutics
ROOM TEMPERATURE STABLE VACCINES:
The long term stability data has shown over 12 months stability at 37°C for the above live vaccines (including adeno and MVA vectors).
cGMP MANUFACTURING CAPABILITY:
-
Nova currently have in-house cGMP manufacturing capability to produce 5,000-10,000 units/batch
-
Our live biologics manufacturing facility is authorised to handle organisms with BSL-1 and BSL-2 categories.
-
The manufacturing process is scalable with the demand.
CLICK on the HydRIS video to see how the technology works.